PMID- 37489655
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231103
IS  - 1747-6356 (Electronic)
IS  - 1747-6348 (Linking)
VI  - 17
IP  - 7
DP  - 2023 Jul-Dec
TI  - Pharmacotherapy and immunotherapy of allergic rhinitis induced by house dust 
      mite, grass, and birch pollen allergens: a meta-analysis of randomized clinical 
      trials.
PG  - 607-621
LID - 10.1080/17476348.2023.2241364 [doi]
AB  - BACKGROUND: The aim of this study was to assess the efficacy and safety of oral 
      antihistamines (AHs), intranasal antihistamines (INAH) intranasal 
      glucocorticosteroids (INCS), subcutaneous immunotherapy (SCIT), and sublingual 
      immunotherapy (SLIT) in the management of allergic rhinitis (AR). The authors 
      focused on the division into selected AR's triggers: house dust mites (HDMs), 
      grass pollen, and birch pollen. METHODS: For each drug and allergen class, a 
      meta-analysis of the efficacy and adverse events (AEs) was performed. The 
      obtained results were presented as a therapeutic index (TIX-Score). RESULTS: 
      Twenty-seven randomized clinical trials (RCTs) were included. The best total 
      efficacy was observed for: HDMs for INCS and grass pollen for combination of INCS 
      with INAH in a single device and for INAH. Considering the data that was obtained 
      for birch pollen, SLIT showed statistically significant total efficacy. Summation 
      scores for efficacy and AEs showed highest TIX-Score for combination of INCS and 
      INAH in a single device in grass pollen. CONCLUSIONS: Treatment methods selected 
      for this review may serve as an effective and safe treatment in reducing 
      perennial and seasonal AR's symptoms. However, due to high heterogeneity probably 
      associated with potential confounders existence in control in some cases, results 
      should be interpreted with caution.
FAU - Marko, Monika
AU  - Marko M
AUID- ORCID: 0000-0003-3596-6625
AD  - Department of Immunopathology, Faculty of Medicine, Division of Biomedical 
      Science, Medical University of Lodz, Lodz, Poland.
FAU - Pawliczak, Rafal
AU  - Pawliczak R
AUID- ORCID: 0000-0001-6784-453X
AD  - Department of Immunopathology, Faculty of Medicine, Division of Biomedical 
      Science, Medical University of Lodz, Lodz, Poland.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230728
PL  - England
TA  - Expert Rev Respir Med
JT  - Expert review of respiratory medicine
JID - 101278196
RN  - 0 (Allergens)
RN  - 0 (Histamine Antagonists)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Allergens
MH  - Betula
MH  - Pyroglyphidae
MH  - Poaceae
MH  - Randomized Controlled Trials as Topic
MH  - *Rhinitis, Allergic/drug therapy
MH  - Pollen
MH  - *Sublingual Immunotherapy/adverse effects/methods
MH  - Histamine Antagonists
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - efficacy
OT  - immunotherapy
OT  - pharmacotherapy
OT  - safety
EDAT- 2023/07/25 13:08
MHDA- 2023/07/25 13:09
CRDT- 2023/07/25 07:03
PHST- 2023/07/25 13:09 [medline]
PHST- 2023/07/25 13:08 [pubmed]
PHST- 2023/07/25 07:03 [entrez]
AID - 10.1080/17476348.2023.2241364 [doi]
PST - ppublish
SO  - Expert Rev Respir Med. 2023 Jul-Dec;17(7):607-621. doi: 
      10.1080/17476348.2023.2241364. Epub 2023 Jul 28.